June 16, 2016
2 min read

Latisse effective for treating eyebrow hypotrichosis

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Latisse, applied once or twice daily for 7 months, was effective and safe compared with vehicle in treating eyebrow hypotrichosis, according to study results.

Jean Carruthers, MD, and colleagues conducted a multicenter, double-masked study of 357 adults (94.7% women; mean age, 54 years) with eyebrow hyperhidrosis, defined as either a grade 1 or 2 (very sparse or sparse) on the Allergan Global Eyebrow Assessment (GEBA) scale. The patients were randomized to receive Latisse (bimatoprost 0.03%, Allergan plc) twice daily (n=118) or once daily (n=118) or vehicle twice daily (n=121) for 7 months.  Overall eyebrow fullness at 7 months was the primary endpoint.

Jean Carruthers, MD

Jean Carruthers

Latisse was approved by the FDA in 2008 for treating hypotrichosis of the eyelashes.

There were 339 adults who completed the study. There were 83.9% of patients in the bimatoprost twice-daily group and 77.1% in the once-daily group with at least a 1-grade improvement in the GEBA scale from baseline at month 7, compared with 43% in the vehicle cohort (P < .001, both comparisons). Both bimatoprost treatment cohorts displayed significant improvements compared with the vehicle cohort after 1 month, which continued during the treatment and post-treatment periods (P ≤ .035, all comparisons).

Both bimatoprost treatment groups had improvement in eyebrow fullness and darkness by month 2 compared with the patients in the vehicle cohort (P ≤ 001, both).

There were 17.8% of patients in the bimatoprost twice-daily cohort, 16.9% in the bimatoprost once-daily cohort and 11.6% in the vehicle cohort who reported being “very satisfied” with their eyebrow look at month 7. Both bimatoprost treatment cohorts reported a significantly greater proportion of patients who reported ‘very satisfied or mostly satisfied” compared with the patients in the vehicle cohort (P ≤ .031).

“Overall, 38.1%, 42.4% and 35.5% of subjects in the bimatoprost [twice-daily], [once-daily] and vehicle groups, respectively, experienced ≥ 1 treatment-emergent adverse event,” the researchers reported.

There were no reports of skin or iris hyperpigmentation or conjunctival hyperemia.

“Bimatoprost 0.03% is a safe, well-tolerated and effective treatment for hypotrichosis of the eyebrows in this population,” the researchers concluded. “Improvements in eyebrow growth and subject satisfaction appeared within 1 to 2 months and were sustained through the study period. The safety profile of bimatoprost … is in line with that shown in previous large, controlled studies of bimatoprost for treatment of eyelash hypotrichosis.”  – by Bruce Thiel

Disclosure: The study was supported by Allergan, plc, with writing and editorial support provided by Peloton Advantage. Carruthers reports serving as a consultant for and receiving research grants from Allergan plc. Please see the full study for a list of other researchers’ relevant financial disclosures.